Original ArticleAdaptive Radiotherapy Using Helical Tomotherapy for Head and Neck Cancer in Definitive and Postoperative Settings: Initial Results
Introduction
Radiotherapy is an integral part of treatment for head and neck squamous cell carcinoma (HNSCC), both in the definitive and adjuvant settings. It is, however, associated with significant morbidity due to effects on normal tissues. Use of intensity-modulated radiotherapy, with its ability to deliver dose in a highly conformal way, allows greater normal tissue sparing than traditional three-dimensional conformal radiotherapy and improves quality of life in HNSCC patients [1]. With this highly conformal treatment there is the potential for changes in dosimetry to occur due to changes in patient anatomy during the course of therapy. It is currently not routine practice to account for these changes during treatment.
Changes in patient anatomy may occur either from a reduction in tumour bulk, weight loss or a reduction in postoperative oedema, and may vary between patients. Adaptive radiotherapy, in this context, refers to reimaging the patient during their radiotherapy course and generating a new radiotherapy plan based on this new imaging, which takes into account changes in anatomy. Decisions on whether to modify (adapt) a treatment plan during the treatment course are generally made empirically based on weight loss, change in neck separation or poor immobilisation shell fit. To date, a small number of studies investigating the benefits of adaptive radiotherapy in the treatment of HNSCC, generally in patients with marked changes in anatomy, have been carried out. These have shown an overall benefit in terms of reducing dose to normal tissues, particularly the parotid gland, and improved tumour target coverage [2], [3], [4]. However, it remains unclear whether all patients derive a significant benefit from adaptive replanning.
With this pilot study, we aimed to assess the feasibility of routinely offering adaptive radiotherapy to HNSCC patients in our department; to determine whether this results in clinically significant benefits in either tumour target coverage or normal tissue sparing; and to determine which patients receive the greatest benefit, with a view to selecting these patients for routine adaptive therapy.
Section snippets
Study Design and Eligibility
Two cohorts of patients were enrolled. Cohort 1 consisted of postoperative patients requiring adjuvant radiotherapy. Any patient receiving adjuvant radiotherapy/chemoradiotherapy was eligible. Cohort 2 consisted of patients receiving radical radiotherapy/chemoradiotherapy for HNSCC. Patients were eligible for cohort 2 if they had primary tumour size ≥3 cm on imaging or examination and/or cervical nodal lymphadenopathy ≥3 cm in size on clinical examination, and had not undergone surgery. This
Patient Demographics
The first 20 patients accrued to this ongoing pilot study, between December 2008 and February 2010, are presented for preliminary analysis. The patient and tumour characteristics are shown in Table 2.
Patient and Tumour Parameter Changes during Radiotherapy
Table 3 shows the changes in patient and plan parameters between CT1 and CT2. On average, lateral neck separation reduced by 6–7 mm (range –5 to 18 mm) between scans. The median parotid volume loss was 17.5% (range –1.0 to 46.0%) with a median reduction in PTV60/66 of 16% (range 0 to 45%) and PTV54
Discussion
We have shown a modest benefit to adaptive radiotherapy in these relatively unselected patients. For the group overall we found significant, although small, benefits to adaptive therapy with a reduced PTV D1, a reduced maximum spinal cord dose and a reduced volume of skin receiving ≥50 Gy. For definitively treated patients there were significant benefits also in a reduced mean parotid dose and volume of normal tissue outside the PTV receiving ≥50 Gy. The absolute magnitude of difference was also
Conclusion
Adaptive radiotherapy proved feasible. Modest benefits in reduction in PTV D1, low dose PTV coverage, spinal cord maximum dose and volume of skin receiving ≥50 Gy were found in this relatively unselected population. Definitively treated patients also had benefits in a reduction in mean parotid dose and the volume of normal tissue outside the PTV receiving ≥50 Gy. Patients with nasopharyngeal carcinoma, initial stage T3/4 and greater weight loss or a reduction in lateral neck separation received
Conflict Of Interest Statement
Lisa Capelle - No conflicts of interest to declare
Marc Mackenzie - No conflicts of interest to declare
Colin Field - No conflicts of interest to declare
Matthew Parliament - No conflicts of interest to declare
Sunita Ghosh - No conflicts of interest to declare
Rufus Scrimger - No conflicts of interest to declare
References (21)
- et al.
Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program
Int J Radiat Oncol Biol Phys
(2009) - et al.
Repeat CT imaging and replanning during the course of IMRT for head and neck cancer
Int J Radiat Oncol Biol Phys
(2006) - et al.
Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma
Int J Radiat Oncol Biol Phys
(2010) - et al.
Adaptive replanning strategies accounting for shrinkage in head and neck IMRT
Int J Radiat Oncol Biol Phys
(2009) - et al.
Dose-volume modeling of the salivary function in patients with head-and-neck cancer receiving radiotherapy
Int J Radiat Oncol Biol Phys
(2005) - et al.
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
Int J Radiat Oncol Biol Phys
(1999) - et al.
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy
Int J Radiat Oncol Biol Phys
(2004) - et al.
Pathophysiology of irradiated skin and breast
Int J Radiat Oncol Biol Phys
(1995) - et al.
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study
Int J Radiat Oncol Biol Phys
(2010) - et al.
Actual dose variation of parotid glands and spinal cord for nasopharyngeal cancer patients during radiotherapy
Int J Radiat Oncol Biol Phys
(2008)
Cited by (67)
An Observational Dosimetric Study in Definitively Treated Primary Head and Neck Cancers: To Assess the Effect of Weight Loss and Change in Lateral Neck Dimensions on the Difference Between Dose Planned and Received by the Parotid(s) and Correlation with Adaptive Radiation Therapy
2024, Advances in Radiation OncologyIn Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy
2024, Advances in Radiation OncologyEarly Experience of Online Adaptive Radiation Therapy for Definitive Radiation of Patients With Head and Neck Cancer
2023, Advances in Radiation OncologyAdaptive radiation therapy: When, how and what are the benefits that literature provides?
2022, Cancer/RadiotherapieEvaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer
2022, Radiotherapy and OncologyWhat information can we gain from performing adaptive radiotherapy of head and neck cancer patients from the past 10 years?
2022, Cancer/RadiotherapieCitation Excerpt :Also, it has been shown that re-planning influences clinical outcomes: local control, disease free survival and overall survival. The most significant decrease in patient body weight is observed between 2–4 weeks of treatment which corresponds to 10fr–20fr [2–5,7,9,12,13,30,34,36–39], and this interval is particularly recommended for rescanning. Studies showed that spinal cord and parotids received more doses actually delivered than planned, which could be reduced by re-planning [11,28,37].